Related Experiment Videos
Disease staging and PMCs. Can they improve DRGs?
1Center for Health Economics Research, Needham, MA 02194.
Medical Care
|August 1, 1987
Summary
Medicare's case-mix measures, Patient Management Categories (PMCs) and Disease Staging, do not outperform Diagnosis Related Groups (DRGs) in explaining cost variation. However, they may help refine DRGs by identifying patient subgroups with different costs.
Area of Science:
- Health Economics
- Medical Informatics
- Healthcare Management
Background:
- Medicare's Prospective Payment System (PPS) faces criticism regarding cost per case variation due to illness severity within Diagnosis Related Groups (DRGs).
- Accurate case-mix measurement is crucial for equitable healthcare reimbursement and resource allocation.
- Existing DRGs may not fully capture patient complexity, leading to potential payment inaccuracies.
Purpose of the Study:
- To evaluate the effectiveness of Patient Management Categories (PMCs) and Disease Staging as alternatives or modifiers to DRGs for explaining Medicare hospital costs.
- To assess the ability of these case-mix measures to account for severity of illness variation within DRGs.
- To determine if PMCs or Disease Staging can improve the predictive performance of DRGs.
Main Methods:
- Utilized hospital (Part A) cost data for all Medicare beneficiaries hospitalized in Michigan in 1982.
- Applied multivariate statistical techniques to compare the explanatory power of DRGs, PMCs, and Disease Staging on cost per case.
- Examined the incremental explanatory power of PMCs and Disease Staging when used in conjunction with DRGs.
Main Results:
- Diagnosis Related Groups (DRGs) explained 33% of the variation in hospital costs.
- Patient Management Categories (PMCs) explained 26% of the cost variation, while Disease Staging explained 17%.
- Neither PMC nor Disease Staging alone explained more variation than DRGs; their combined use with DRGs added only 1-2% explanatory power. However, both identified patient subgroups with significantly different costs.
Conclusions:
- PMCs and Disease Staging, while not superior to DRGs in overall cost variation explanation, show potential as modifiers to identify outlier patients.
- These alternative measures may help refine DRGs by highlighting patients with unrelated comorbidities, potentially improving the accuracy of the Prospective Payment System.
- Further research into integrating comorbidity measures could enhance the performance of DRGs and lead to more accurate healthcare reimbursement.